Anecdotal and uncontrolled studies have suggested that nonsteroidal anti-inflammatory drugs produce false-positive resuits in immunoassay urine tests for some drugs of abuse. This study was performed in 60 volunteers who took ibuprofen as either a single 400-mg dose, or 200 mg three times a day, or 400 mg three times a day, and in 42 patients taking ibuprofen, naproxyn, or fenoprofen in therapeutic regimens for more than 30 days. Of the 510 urines collected from 102 individuals during these dosage regimens, two gave falsepositive tests for cannabinoid by enzyme-mediated immunoassay (EMIA), one after 1200 mg of ibuprofen in three divided doses for one day and one in a patient taking naproxyn on a chronic basis; none was falsely positive for benzodiazepines. Two unnes were false-positive for barbiturates by fluorescence polarization immunoassay (FPIA), one in a patient taking ibuprofen and one in a patient taking naproxyn. These data, collected prospectively, demonstrate the small likelihood of a false-positive immunoassay test result for cannabinoids, benzodiazepines, or barbiturates after the acute or chronic ingestion of ibuprofen, or after the chronic ingestion of naproxyn or fenoprofen.
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Testing of body fluids for the presence of drugs of abuse is becoming increasingly popular in the military, athletic competitions, and the workplace. The body fluid most frequently tested is urine: it is easy to obtain and contains relatively high concentrations of drugs and drug metabolites. However, testing urine for drugs of abuse presents several problems.
First, drug excretion in urine usually bears little relationship to the pharmacodynamic or toxic effects of the drug. Second, other drugs or food substances excreted in the urine could potentially interfere with analytical methods.
Third, the presence of a drug or drug metabolite in urine indicates drug use, but does not usually indicate behavioral or physical impairment.
The goal of any drug-testing program should be 100% accuracy, with no false-positive or false-negative reports. A forensic urine drug-testing program should consist of an initial screening technique to determine which specimens are presumptively positive. These specimens are then subjected to confirmation by a second type of analytical procedure, different from that used to screen the specimens. Such reports, however, are mostly anecdotal. Because of the significance of a false-positive result for substance abuse, it is necessary to know the likelihood that ingesting NSAIDs will produce a false-positive result for urine drug tests, and what conditions are necessary for this to occur.
For example,
is the person taking a single dose of an NSAID the night before a drug test at risk to have a false-positive immunoassay result, and are patients taking therapeutic doses at risk? Our purpose in this study was to determine whether ibuprofen taken as a single dose or in multiple doses the day before a drug test, or ibuprofen, naproxyn, or fenoprofen taken by patients in usual therapeutic doses, will produce false-positive results in immunoassay urine tests for cannabinoids, barbiturates, or benzodiazepines.
Materials and Methods

Subjects and Experimental Design
In this study, approved by the University of Utah Institutional Review Board, each volunteer or patient gave informed consent before participating. The study was divided into an acute and a chronic phase. The subjects were healthy male and female volunteers, ages 18 to 81 years.
Before entering the study, subjects were given a physical examination, and a medical history was taken to determine that they had no contraindication to the administration of ibuprofen.
Subjects with hypertension, diabetes, liver or kidney disease, peptic ulcers, or other chronic debilitating diseases were excluded.
In the acute phase, each subject took the following doses of ibuprofen on three consecutive days: a 400-mg single dose at bedtime (day 1); 200mg at 0800 hours, 12noon, and bedtime (day 2); and 400 mg at 0800, 12 noon, and bedtime 3, and 4) , and more than 24 h after the last ibuprofen dose (day 5).
In the chronic phase of the study, the subjects had been taking ibuprofen in a minimum dose of 1200 mg daily, naproxyn in a minimum dose of 1000 mg daily, or fenoprofen in a minimum dose of 1200 mg daily, for at least 30 days before entering the study. Each patient provided a first-voided morning urine on five consecutive days. Each urine was analyzed for cannabinoids and barbiturates by RIA, EMIA, and FPIA; for benzodiazepines by EMIA and FPIA; and for either ibuprofen, naproxyn, or fenoprofen by high-pressure liquid chromatography (HPLC). Presumptive-positive immunoassay urines were subjected to confirmation analysis by gas chromatography/ mass spectrometry (GCIMS).
Analytical Methods
Immunoassay:
RIA ( 5-pm particle size column (250 x 46 mm). Urine drug standards between 50 and 500 mgfL were analyzed with each HPLC run; the assay results displayed linearity between these concentrations. Concentrations of ibuprofen >500 mg/L in urine were diluted with water and reanalyzed; concentrations of naproxyn and fenoprofen in urine were quantified only to 500 mgfL.
Gas chromatography/mass spectrometry: Cannabinoids. To confirm the presence or absence and quantification of the carboxy metabolite of delta-9-tetrahydrocannabinol (COOH-THC), we used a Model 3200 mass spectrometer (Finnigan, San Jose, CA), with DB 5 fused-silica capillary column (13 m x 0.2 mm, 1.0-pm-thick film) . To 1 mL of urine we added 20 ng of the COOH-THC-d3 internal standard, 1 mL of 2 mol/L NaOH, and 2 mL of hexane. This mixture was shaken at room temperature for 30 mm, then frozen in a bath of solid CO2 and methanol. After discarding the organic phase, we melted the aqueous-ice phase and added to it 0.5 mL of 6 mol/L HC1 and 0.5 mL of hexane/ethyl acetate (5/1 by vol). The mixture was shaken for 15 mm, frozen, and the aqueous-ice phase was discarded. The organic phase was evaporated almost to dryness, and 25 pL of hexafluoroisopropanol and 50 tL of pentaIluoropropionic anhydride were added. After leaving the mixture at room temperature for 30 mm, we evaporated the solvent and reconstituted the residue in 20 pL of n-heptane and injected 1 to 2 LL into the GC/MS. The gas chromatograph injector temperature was maintained at 250 'C; the oven was programmed from 175 to 260 #{176}C at 20 #{176}C/min. The lower limit of sensitivity of this method is 1 ng/mL.
Barbiturates. Analysis of presumptive positive urines for barbiturates by GCIMS was by a modification 
Results
The age and sex distribution of the subjects is shown in Table 1 . We obtained 510 urine specimens from the 102 subjects: 300 from volunteers in the acute ibuprofen phase of the study, 120 from 24 patients participating in the Table 2 . Ten urine specimens were presumptively positive for cannabunoids; however, seven of these specimens (from subjects 86 and 124) were confirmod by GC/MS to contain cannabinoids. Three urine specimens (subjects 7, 31, and 82) were positive for cannabimoids by EMIA, although cannabinoids were not confirmed by GC/MS. The concentrations of COOH-THC in urine from subjects 124 and 86 are also shown in Table 2 . The concentration of this metabolite in the urine from subject 124 was quite low, and probably represents the use of marijuana several days before entering the study. The pattern of urinary excretion of cannabinoid metabolite in subject 86 is more complex, and may represent marijuana use before entering the study as well as during the study.
Four urines from two patients taking ibuprofen were presumptively positive for benzodiazepines (Table 3) ; one subject taking naproxyn had urine positive for benzodiazepines. In each case, a benzodiazepune or metabolite was detected in the urine by GC/MS. Thus, there were no false-positive benzodiazepune immunoassay results. Table 4 shows the data from tests on urines obtained from subjects and patients taking NSAIDs that were immunoassay-positive for barbiturates. All five urines supplied by subject 31 were immunoassay-positive, but none was confirmed to contain barbiturates by GCIMS. However, each urine from this subject contained phenytoin, and he later admitted to taking phemytoin. Enzymatic activity is therefore directly related to the concentration of the cannabinoid metabolite in the urine (10) (11) (12) . Because of marked structural differences between the propionic acid derivatives (ibuprofen, naproxyn, or fenoprofen) and the cannabinoid metabolite, it seems unlikely that competitive interference would occur with the cannabinoid assay. The known metabolites of ibuprofen, naproxyn, and fenoprofen are also unlikely candidates for competition with cannabinoids for antibody binding sites (13). Other possible mechanisms of NSAID interference with the EMIA include (a) interference with the enzyme reaction; (b) production of an erroneous absorbance reading; or (c) secretion of an endogenous substance that inhibits cannabinoid binding to an antibody, interferes with the enzyme reaction, or causes an erroneous absorbance reading. The Syva Company reportedly changed its formulation of EMIT kits for the urine cannabinoid test when interference with ibuprofen was reported (2) . The data from the present study, using the revised assay, indicate that this change is probably effective. However, the two EMLA false-positive 
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